ClinicalTrials.gg
RecruitingNCT06003283RITUXERAUpdated May 31, 2025

Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis

A Phase 4 interventional study of Rituximab in Rheumatoid Arthritis, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 7 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-31.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.

Planned enrollment
36th of 63
134 · median 159
Started
2024
the only one that year
Phase 4
14 of 63
3 open now
Registered
59th of 63
by date

Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 36th largest by planned enrollment, is the only one that started in 2024, is one of 14 in phase 4, and was the 59th registered.

Arthritis, Rheumatoid

3,338 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing rituximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The goal of this open label multicenter randomized controlled pragmatic superiority trial is to investigate the optimal treatment/tapering strategy with rituximab for patients with rheumatoid arthritis.

The main questions it aims to answer are:

  • What is the optimal treatment/tapering strategy for rituximab in patients with rheumatoid arthritis in terms of reducing patient reported disease impact?
  • What is the optimal treatment/tapering strategy for rituximab in patients with rheumatoid arthritis in terms of therapeutic efficacy?

Participants will be randomized to one of two study arms:

  • Tapering based on disease-activity guided dose reduction (experimental arm)
  • Tapering based on interval prolongation (active comparator arm)
03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid arthritis
  • Rituximab
  • Tapering
  • Disease impact
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able and willing to give written and participate in the study before any study procedure.
  • Age ≥ 18 years.
  • Understanding and able to write in Dutch or French.
  • Diagnosis of rheumatoid arthritis according to the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Classification Criteria for rheumatoid arthritis.
  • Previous response to rituximab, defined as a minimum of one successful rituximab cycle (= a moderate/good EULAR response 16 weeks after the first administration of rituximab).
  • Current treatment with rituximab.
  • Need for a subsequent rituximab cycle according to the Belgian reimbursement criteria for the use of rituximab in rheumatoid arthritis (DAS28 score ≥3.2).
  • Stable dose of methotrexate or other conventional synthetic disease-modifying antirheumatic drugs (DMARDs) 4 weeks prior to baseline.

Exclusion criteria

Exclusion Criteria:

  • Current treatment with another biological DMARD than rituximab.
  • Current treatment with a targeted synthetic DMARD.
  • Pregnancy or pregnancy wish.
  • Presence of an absolute to treatment with rituximab, according to the label of rituximab and according to medical judgement.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
134 participants (estimated)

Study arms

  • Experimental
    Tapering of rituximab based on disease activity guided dose reduction

    Treatment with rituximab every 6 months (24 weeks) with dosing based on disease activity, measured by the DAS28-CRP. DAS28-CRP ≤ 3.2: dose reduction according to the following sequence: 1 x 1000 mg IV (maximum), 1 x 500 mg IV, 1 x 200 mg IV (minimum). DAS28-CRP \> 3.2: administration of previously effective dose.

    Drug: Rituximab

  • Active comparator
    Tapering of rituximab based on interval prolongation

    Treatment with fixed dose of rituximab (1 x 1000 mg IV) if DAS28-CRP ≥ 3.2 AND interval of at least 6 months (24 weeks) since previous administration of rituximab.

    Drug: Rituximab

Interventions

  • IV rituximab

    Also known as: MabThera, Truxima, Ruxience, Rixathon

06

What researchers measure

Primary outcomes

  1. Comparison of disease impact in both study arms, measured using the Rheumatoid Arthritis Impact of Disease (RAID) questionnaire

    RAID questionnaire score range: 0 - 10, with higher scores indicating worse status.

    Time frame: Over 2 years (104 weeks)

Secondary outcomes

  1. Comparison of disease activity in both study arms, measured using the Disease Activity Score in 28 joints - C-reactive protein (DAS28-CRP)

    Main secondary outcome. DAS28-CRP range: 0 - ..., with higher values indicating higher disease activity.

    Time frame: Over 2 years (104 weeks)

  2. Comparison of disease activity in both study arms, measured using the Simplified Disease Activity Index (SDAI)

    SDAI range: 0 - ..., with higher values indicating higher disease activity.

    Time frame: Over 2 years (104 weeks)

  3. Comparison of cumulative dose of rituximab in both study arms

    Time frame: Over 2 years (104 weeks)

  4. Comparison of cumulative dose of glucocorticoids in both study arms

    Time frame: Over 2 years (104 weeks)

  5. Proportion of patients in both study arms achieving a good or moderate European League Against Rheumatism (EULAR) treatment response after administration of rituximab, over a period of 2 years (104 weeks)

    A good EULAR response is defined as a decrease in Disease Activity Score in 28 joints - C-reactive protein (DAS28-CRP) \> 1.2 and a present DAS-CRP ≤ 3.2. A moderate EULAR response is defined as a decrease in DAS28-CRP \> 0.6 to ≤ 1.2 and a present DAS28-CRP ≤ 5.1, or a decrease in DAS28-CRP \> 1.2 and a present DAS28-CRP \> 3.2. Treatment responses will be evaluated 12 weeks after every administration of rituximab.

    Time frame: Over 2 years (104 weeks)

  6. Comparison of loss of disease control in both study arms

    Loss of disease control is defined as achieving a Disease Activity Score in 28 joints - C-reactive protein (DAS28-CRP) \> 3.2 with previous DAS28-CRP ≤ 3.2.

    Time frame: Over 2 years (104 weeks)

  7. Comparison of rituximab drug retention rate in both study arms

    Defined as the percentage of patients remaining on treatment with rituximab over time.

    Time frame: Over 2 years (104 weeks)

  8. Proportion of patients tapering rituximab below 1000 mg in the experimental arm

    Time frame: Over 2 years (104 weeks)

  9. Mean/median interval between rituximab administrations in the active comparator group

    Time frame: Over 2 years (104 weeks)

  10. Comparison of serious adverse events/reactions rates in both study arms.

    An adverse event or adverse reaction is considered serious if it leads to inpatient hospitalization or prolongation of existing hospitalization, if it results in persistent or significant disability or incapacity, if it results in a life-threatening experience (meaning that the subject was at risk of death), or if it results in death.

    Time frame: Over 2 years (104 weeks)

  11. Comparison of serious infections rate in both study arms.

    An infection is considered serious if it leads to inpatient hospitalization or prolongation of existing hospitalization, if it results in persistent or significant disability or incapacity, if it results in a life-threatening experience (meaning that the subject was at risk of death), or if it results in death.

    Time frame: Over 2 years (104 weeks)

Other outcomes

  1. Comparison of functional status in both study arms, measured using the Health Assessment Questionnaire - Disability Index (HAQ-DI)

    HAQ-DI score range: 0 - 3, with higher scores indicating worse functional status.

    Time frame: Over 2 years (104 weeks)

  2. Self-efficacy in both study arms, measured using the Arthritis Self-Efficacy Scale (ASES)

    ASES score range: 11 - 110, with higher scores indicating higher perceived self-efficacy.

    Time frame: Over 2 years (104 weeks)

  3. Pain in both study arms, measured using a Visual Analogue Scale (VAS) completed by the patient

    VAS pain range: 0 - 100, with higher values indicating higher pain

    Time frame: Over 2 years (104 weeks)

  4. Fatigue in both study arms, measured using a Visual Analogue Scale (VAS) completed by the patient

    VAS fatigue range: 0 - 100, with higher values indicating more fatigue.

    Time frame: Over 2 years (104 weeks)

  5. Patient global assessment (PGA) of disease in both study arms, measured using a Visual Analogue Scale (VAS) completed by the patient

    VAS PGA range: 0 - 100, with higher values indicating worse disease.

    Time frame: Over 2 years (104 weeks)

  6. Cluster of Differentiation (CD) 19+ and Memory B cell counts in both study arms

    Determined at baseline, before administration of rituximab and at year 2 (104 weeks) in both study arms.

    Time frame: Over 2 years (104 weeks)

  7. Immunoglobulin (Ig) counts (IgG, IgA and IgM) in both study arms

    Determined at baseline, before administration of rituximab and at year 2 (104 weeks) in both study arms.

    Time frame: Over 2 years (104 weeks)

  8. Professional and vocational participation in both study arms, calculated using the Work Productivity and Activity Impairment questionnaire: General Health (WPAI:GH)

    The WPAI:GH calculates the percent work time missed due to health (range 0-100, higher numbers indicating more missed work time), the percent impairment while working due to health (range 0-100, higher numbers indicating higher impairment), the percent overall work impairment due to health (range 0-100, higher numbers indicating higher impairment), and the percent activity impairment due to health (range 0-100, higher numbers indicating higher impairment).

    Time frame: Over 2 years (104 weeks)

  9. Health utility index in both study arms, calculated using the summary index score of the EuroQol - 5 dimensions (EQ-5D) questionnaire

    Summary index score range: less than 0 (health state worse than dead, 0 being the value of a health state equivalent to death) to 1 (full health).

    Time frame: Over 2 years (104 weeks)

07

Study locations

5 of 7 sites recruiting
  • ZNA Jan Palfijn
    Merksem, Antwerpen 2170, Belgium
    Not yet recruiting
    • Alla Ishchenko, MD · Contact
  • Reumacentrum Genk
    Genk, Limburg 3600, Belgium
    Recruiting
    • Philip Remans, MD, PhD · Contact
  • ReumaClinic Genk
    Genk, Limburg 3600, Belgium
    Recruiting
    • Johan Vanhoof, MD · Contact
  • OLV Aalst
    Aalst, Oost-Vlaanderen 9300, Belgium
    Recruiting
    • Tom Zwaenepoel, MD · Contact
  • RZ Heilig Hart
    Leuven, Vlaams-Brabant 3000, Belgium
    Recruiting
    • Veerle Taelman, MD · Contact
  • University Hospitals Leuven (UZ Leuven)
    Leuven, Vlaams-Brabant 3000, Belgium
    Recruiting
    • Patrick Verschueren, MD, PhD · Contact
    • Johan Joly, MSc · Contact
    • Elias De Meyst, MD · Sub investigator
  • Cliniques Universitaires Saint-Luc Bruxelles
    Brussel, 1000, Belgium
    Not yet recruiting
    • Patrick Durez, MD, PhD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2027, 47 months after the start.

Of 79 non-industry phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 92. This study's planned 47 months is close to that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2023
First posted
Aug 21, 2023
StartActual
Jan 9, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
May 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06003283
Collaborators
Fonds voor Wetenschappelijk Reumaonderzoek (FWRO)
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
Jan 9, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
May 31, 2025

Study contacts

Patrick Verschueren, MD, PhD
Contact
patrick.verschueren@uzleuven.be
016342541 ext. +32
Johan Joly, MSc
Contact
johan.joly@uzleuven.be
016340258 ext. +32
Patrick Verschueren, MD, PhD
principal investigator · University Hospitals Leuven/KU Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion